Literature DB >> 19264913

Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain.

Chang-E Zhang1, Wei Wei, Ying-Hua Liu, Jun-Hua Peng, Qing Tian, Gong-Ping Liu, Yao Zhang, Jian-Zhi Wang.   

Abstract

Hyperhomocysteinemia and beta-amyloid (Abeta) overproduction are critical etiological and pathological factors in Alzheimer disease, respectively; however, the intrinsic link between them is still missing. Here, we found that Abeta levels increased and amyloid precursor protein (APP) levels simultaneously decreased in hyperhomocysteinemic rats after a 2-week induction by vena caudalis injection of homocysteine. Concurrently, both the mRNA and protein levels of presenilin-1, a component of gamma-secretase, were elevated, whereas the expression levels of beta-secretase and presenilin-2 were not altered. We also observed that levels of phosphorylated APP at threonine-668, a crucial site facilitating the amyloidogenic cleavage of APP, increased in rats with hyperhomocysteinemia, although the phosphorylation per se did not increase the binding capacity of pT668-APP to the secretases. The enhanced phosphorylation of APP in these rats was not relevant to either c-Jun N-terminal kinase or cyclin-dependent kinase-5. A prominent spatial memory deficit was detected in rats with hyperhomocysteinemia. Simultaneous supplementation of folate and vitamin-B12 attenuated the hyperhomocysteinemia-induced abnormal processing of APP and improved memory. Our data revealed that hyperhomocysteinemia could increase Abeta production through the enhanced expression of gamma-secretase and APP phosphorylation, causing memory deficits that could be rescued by folate and vitamin-B12 treatment in these rats. It is suggested that hyperhomocysteinemia may serve as an upstream factor for increased Abeta production as seen in patients with Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264913      PMCID: PMC2671378          DOI: 10.2353/ajpath.2009.081036

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  79 in total

1.  Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5.

Authors:  K Iijima; K Ando; S Takeda; Y Satoh; T Seki; S Itohara; P Greengard; Y Kirino; A C Nairn; T Suzuki
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

2.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation.

Authors:  G Pigino; A Pelsman; H Mori; J Busciglio
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

4.  Reconstitution of gamma-secretase activity.

Authors:  Dieter Edbauer; Edith Winkler; Joerg T Regula; Brigitte Pesold; Harald Steiner; Christian Haass
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

5.  Phosphorylation of thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase 1b (Jun N-terminal kinase-3).

Authors:  C L Standen; J Brownlees; A J Grierson; S Kesavapany; K F Lau; D M McLoughlin; C C Miller
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

6.  S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production.

Authors:  Andrea Fuso; Laura Seminara; Rosaria A Cavallaro; Fabrizio D'Anselmi; Sigfrido Scarpa
Journal:  Mol Cell Neurosci       Date:  2005-01       Impact factor: 4.314

7.  Homocysteic acid induces intraneuronal accumulation of neurotoxic Abeta42: implications for the pathogenesis of Alzheimer's disease.

Authors:  Tohru Hasegawa; Wataru Ukai; Dong-Gyu Jo; Xiangru Xu; Mark P Mattson; Masaya Nakagawa; Wataru Araki; Toshikazu Saito; Tatsuo Yamada
Journal:  J Neurosci Res       Date:  2005-06-15       Impact factor: 4.164

Review 8.  beta-Secretase, APP and Abeta in Alzheimer's disease.

Authors:  Robert Vassar
Journal:  Subcell Biochem       Date:  2005

9.  BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice.

Authors:  Kouhei Nishitomi; Gaku Sakaguchi; Yuko Horikoshi; Audrey J Gray; Masahiro Maeda; Chiho Hirata-Fukae; Amanda G Becker; Motoko Hosono; Isako Sakaguchi; S Sakura Minami; Yoshihiro Nakajima; Hui-Fang Li; Chie Takeyama; Tsuyoshi Kihara; Akinobu Ota; Philip C Wong; Paul S Aisen; Akira Kato; Noriaki Kinoshita; Yasuji Matsuoka
Journal:  J Neurochem       Date:  2006-11-02       Impact factor: 5.372

10.  Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels.

Authors:  Javier Pacheco-Quinto; Elena B Rodriguez de Turco; Steven DeRosa; Altovise Howard; Felix Cruz-Sanchez; Kumar Sambamurti; Lorenzo Refolo; Suzana Petanceska; Miguel A Pappolla
Journal:  Neurobiol Dis       Date:  2006-03-03       Impact factor: 5.996

View more
  59 in total

1.  The involvement of homocysteine in stress-induced Aβ precursor protein misprocessing and related cognitive decline in rats.

Authors:  Fang Xie; Yun Zhao; Jing Ma; Jing-Bo Gong; Shi-Da Wang; Liang Zhang; Xiu-Jie Gao; Ling-Jia Qian
Journal:  Cell Stress Chaperones       Date:  2016-07-19       Impact factor: 3.667

Review 2.  Age-related lysosomal dysfunction: an unrecognized roadblock for cobalamin trafficking?

Authors:  Hua Zhao; Ulf T Brunk; Brett Garner
Journal:  Cell Mol Life Sci       Date:  2011-10-21       Impact factor: 9.261

Review 3.  Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Authors:  Jia-Min Zhuo; Hong Wang; Domenico Praticò
Journal:  Trends Pharmacol Sci       Date:  2011-06-20       Impact factor: 14.819

4.  Folate/Vitamin B Alleviates Hyperhomocysteinemia-Induced Alzheimer-Like Pathologies in Rat Retina.

Authors:  Jing Guo; Shaozhou Ni; Qihang Li; Jian-Zhi Wang; Ying Yang
Journal:  Neurosci Bull       Date:  2018-09-28       Impact factor: 5.203

5.  Cross-Sectional Associations of Total Plasma Homocysteine with Cortical β-Amyloid Independently and as a Function of Omega 3 Polyunsaturated Fatty Acid Status in Older Adults at Risk of Dementia.

Authors:  C Hooper; P De Souto Barreto; N Coley; E Caussé; P Payoux; A S Salabert; M Cesari; S Andrieu; G-L Bowman; M Weiner; B Vellas
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 4.075

6.  Tautomeric Effect of Histidine on β-Sheet Formation of Amyloid Beta 1-40: 2D-IR Simulations.

Authors:  Yeonsig Nam; Mahroof Kalathingal; Shinji Saito; Jin Yong Lee
Journal:  Biophys J       Date:  2020-07-18       Impact factor: 4.033

7.  Association of homocysteine, folate, and white matter hyperintensities in Parkinson's patients with different motor phenotypes.

Authors:  Yuan Shen; Zhi-Feng Dong; Ping-Lei Pan; Gang Xu; Jun-Ying Huang; Chun-Feng Liu
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307

8.  Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet.

Authors:  Jia-Min Zhuo; Domenico Praticò
Journal:  Exp Gerontol       Date:  2009-12-11       Impact factor: 4.032

Review 9.  Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease.

Authors:  Federico Cacciapuoti
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

10.  Dietary deficiency increases presenilin expression, gamma-secretase activity, and Abeta levels: potentiation by ApoE genotype and alleviation by S-adenosyl methionine.

Authors:  Amy Chan; Flaubert Tchantchou; Eugene J Rogers; Thomas B Shea
Journal:  J Neurochem       Date:  2009-05-18       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.